ANDROGEL 1.62% CIII
Generic Name and Formulations:
Testosterone 1.62% (20.25mg of testosterone per one pump actuation); gel.
Indications for ANDROGEL 1.62%:
Testosterone replacement therapy in adult males with congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.
Limitations Of use:
Not established in men with age-related hypogonadism.
Advise patients to strictly adhere to recommended instructions. Apply to clean, intact, dry skin of the shoulders and upper arms; do not apply to abdomen, genitals, chest, axillae, or knees. ≥18yrs: 2.5g (40.5mg of testosterone [2 pump actuations]) once daily in the AM. May adjust dose between minimum of 20.25mg (1 pump actuation) and a maximum of 81mg (4 pump actuations) based on the pre-dose morning serum testosterone concentration at approx. 14 days and 28 days after starting treatment or following dose adjustment. See full labeling. Check additional serum testosterone levels periodically thereafter. Wash hands after application. Allow gel to dry before it touches clothing.
<18yrs: not established.
Male breast or prostate cancer. Pregnant women must avoid skin contact with application sites in men. Pregnancy (Cat.X). Nursing mothers.
Not for use in women. Not interchangeable with other topical testosterone products. Other persons (esp. children) must avoid contact with application site. Secondary exposure to testosterone; promptly discontinue if signs of virilization in children and women occurs, until cause is identified. Increased risk for worsening BPH; monitor for signs/symptoms. Evaluate for prostate cancer before starting therapy. Preexisting cardiac, renal, or hepatic disease (discontinue if edema occurs). May worsen sleep apnea. Monitor hematocrit prior to initiation, at 3–6 months after starting therapy, then annually; if elevation occurs, withhold until acceptable level. Testosterone and/or other anabolic androgenic steroid abuse. Monitor serum testosterone, PSA, liver function, cholesterol, lipid profile, serum calcium (in cancer patients at risk for hypercalcemia). Monitor for venous thromboembolism; discontinue if suspected. Inform patients of possible increased risk of MI, stroke. Flammable. Elderly.
May alter insulin sensitivity and glycemic control; reduce dose of antidiabetic agents if needed. Increased fluid retention with concomitant ACTH, corticosteroids; monitor. Monitor INR and PT with concomitant oral anticoagulants. May affect thyroid levels.
Acne, local reactions, lab abnormalities, prostate disorders, increased PSA, emotional lability, hypertension, breast pain, gynecomastia, nervousness, testis disorders; edema, virilization in children.
Gel 1% (YES); Gel 1.62% (NO)
Gel 1% (2.5g, 5g)—30 packets; Gel 1.62% (1.25g, 2.5g)—30 packets; Pump 1.62% 88g (60 metered 1.25g doses)—1
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness